CONMED (NYSE:CNMD) Issues Earnings Results, Beats Estimates By $0.07 EPS

CONMED (NYSE:CNMD) posted its quarterly earnings data on Wednesday. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07, FiscalAI reports. CONMED had a net margin of 4.00% and a return on equity of 13.85%. The firm had revenue of $317.05 million for the quarter, compared to analysts’ expectations of $310.64 million. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.95 EPS.

Here are the key takeaways from CONMED’s conference call:

• CONMED completed the divestiture of its gastroenterology product lines and will provide transition services into 2027, allowing the company to reallocate capital and focus on higher?growth, higher?margin businesses.
• First?quarter revenue was $317 million (down 1.3% y/y) and adjusted EPS was $0.89 (down 6.3% y/y), although organic sales excluding GI rose about 2.1% in constant currency.
• Management raised 2026 organic revenue guidance to 5.0%–6.5% and maintained full?year adjusted EPS guidance of $4.30–$4.45, citing improving growth drivers and modest FX tailwinds.
• CONMED intends to refinance its convertible notes with bank debt in Q2 (avoiding new convertibles), which management expects will increase interest expense and reduce adjusted EPS by at least $0.10.
• The company highlighted its three core growth platforms—AirSeal (10,000+ installed base, large underpenetrated laparoscopic opportunity), Buffalo Filter (legislative tailwinds and PlumeSafe X5 traction), and BioBrace (growing clinical adoption and an RCT finishing enrollment in 2026)—while supply?chain recovery and a 100 bps gross?margin improvement supported continued orthopedic mid?single?digit growth.

CONMED Stock Up 0.4%

CNMD traded up $0.14 during trading on Friday, reaching $36.80. 236,680 shares of the stock traded hands, compared to its average volume of 512,698. The stock’s 50-day simple moving average is $38.63 and its two-hundred day simple moving average is $41.13. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.14 and a quick ratio of 1.01. CONMED has a fifty-two week low of $33.21 and a fifty-two week high of $61.08. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 20.79, a price-to-earnings-growth ratio of 1.58 and a beta of 0.99.

CONMED News Summary

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q1 results beat expectations — CONMED reported $0.89 EPS vs. $0.82 consensus and revenue of $317.05M vs. ~$310.6M expected; earnings and revenue beats support near-term sentiment. Read More.
• Positive Sentiment: Strategic refocus and outlook raise — CONMED said it is exiting certain GI products to concentrate on higher-growth surgical platforms, raised its 2026 organic growth outlook to roughly 5.0%–6.5%, and is refinancing debt to improve capital structure; this clarifies growth drivers and may improve margin/leverage over time. Read More.
• Neutral Sentiment: Earnings call color and materials available — transcripts and the earnings presentation provide detail on segment performance (domestic sales down driven by GI exit) and management’s execution plan; useful for modeling but not an immediate catalyst by itself. Read More.
• Neutral Sentiment: Top-line softness from portfolio changes — reported sales were down ~1.3% y/y (and ~2.9% in constant currency), with roughly $15M of GAAP sales removed from the GI exit; this explains lower reported revenue while underlying organic metrics look better. Read More.
• Negative Sentiment: Wells Fargo cut its price target from $42 to $39 and set an “equal weight” rating — the revision reduces sell-side upside and may cap near-term investor enthusiasm. Read More.
• Negative Sentiment: JPMorgan trimmed its price target from $43 to $40 and kept a “neutral” rating — another major bank lowering its target increases downward pressure on consensus valuation. Read More.

Analysts Set New Price Targets

CNMD has been the subject of several recent analyst reports. Wells Fargo & Company decreased their target price on CONMED from $42.00 to $39.00 and set an “equal weight” rating for the company in a research report on Friday. Zacks Research raised CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, January 21st. Piper Sandler cut CONMED from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $55.00 to $39.00 in a research note on Tuesday, March 17th. Finally, JPMorgan Chase & Co. dropped their target price on CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $46.20.

Institutional Investors Weigh In On CONMED

A number of hedge funds and other institutional investors have recently made changes to their positions in CNMD. California State Teachers Retirement System raised its holdings in shares of CONMED by 1.6% during the 2nd quarter. California State Teachers Retirement System now owns 28,522 shares of the company’s stock valued at $1,485,000 after purchasing an additional 442 shares in the last quarter. State of Wyoming boosted its holdings in CONMED by 41.3% in the fourth quarter. State of Wyoming now owns 1,567 shares of the company’s stock worth $64,000 after purchasing an additional 458 shares in the last quarter. Aster Capital Management DIFC Ltd increased its position in CONMED by 409.2% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock worth $29,000 after buying an additional 581 shares during the last quarter. Kelleher Financial Advisors acquired a new position in CONMED during the third quarter worth $28,000. Finally, Quarry LP raised its holdings in CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after buying an additional 617 shares in the last quarter.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.